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Objectives: To determine whether pre-angioplasty levels of haemostatic and rheological factors predicted restenosis of 
the dilated arterial segment following percutaneous transluminal angioplasty. 
Design and setting: Prospective study. Two regional hospital centres for angioplasty in Edinburgh and Glasgow, 
Scotland, UK. 
Method: Haemostatic and rheological factors were measured in 102 subjects with atherosclerotic disease of the lower 
limbs, immediately prior to percutaneous transluminal ngioplasty. Subjects were followed up after 2-3 years for restenosis 
of the original angioplasty site using duplex scanning. 
Results: Baseline clinical characteristics were similar between subjects who restenosed (n=27) and those with no 
restenosis (n=39), except hat occluded lesions were more likely to restenose than stenoses (p<_0.05). There was no 
significant difference in age- and sex-adjusted mean levels of whole blood viscosity, plasma viscosity, haematocrit, yon 
Willebrand factor, fibrin D-dimer or plasminogen activator inhibitor-1 activity between the stenosed and no restenosis 
groups (p>0.1), but mean plasma fibrinogen was lower in the restenosed group (3.31 gfl vs. 3.75 gfl; p<0.05). These 
results persisted after multivariate adjustment for smoking habit and type of lesion dilated. 
Conclusions: This study provides no evidence that raised, pre-angioplasty levels of haemostatic and rheological factors 
predict restenosis following percutaneous transluminal angioplasty of the arteries of the lower limbs. 
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Introduction 
Percutaneous transluminal balloon angioplasty is an 
established revascularisation technique used in the 
treatment of atherosclerotic disease of the arteries of 
the lower limb. However, the procedure is associated 
with a 25%-57% 3-year ecurrent stenosis rate affecting 
the dilated arterial segment. ~ Why some lesions re- 
stenose while others remain patent is unknown, and 
clinical trials of pharmacological gents aimed at pre- 
venting restenosis have proved largely unsuccessful. 2 
Haemostatic and theological factors are raised in 
subjects with peripheral arterial disease s-6 and may 
be involved in the development of both primary 
* Please address all correspondence to: Dr J.F. Price, Wolfson Unit 
for the Prevention of Peripheral Vascular Diseases, Department 
of Public Health Sciences, University of Edinburgh, Teviot Place, 
Edinburgh, EH8 9AG, U.K. 
atherosclerotic lesions and restenotic lesions, since 
these demonstrate histological similarities such as 
smooth muscle proliferation and intimal hyperplasia. 7'8
Platelet aggregation and thrombosis, observed at the 
site of angioplasty in animal models, s further suggest 
a role for the coagulation and fibrinolytic systems in 
restenosis. Specifically, plasminogen activator inhib- 
itor-1 (PAIq) binds to circulating tissue plasminogen 
activator, inhibiting fibrinolysis and protecting fibrin 
thrombi from rapid lysis, 9 while von Willebrand 
factor (vWF) mediates platelet adhesion to exposed 
subendothelium at sites of vascular injury, s° Plasma 
fibrinogen contributes to fibrin deposits, the release of 
vasoconstrictor mediators and growth factors and the 
promotion of platelet aggregation, 1~ while fibrin D- 
dimer, an indicator of fibrin formation and turnover, 
is found in high levels in arterial thrombi. 12 Elevated 
blood viscosity, the intrinsic resistance of blood to flow 
in vessels, and two of its major determinants, plasma 
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viscosity and haematocrit, may enhance both athero- 
genesis and thrombosis by prolonging contact between 
constituents of the blood and the endothelial surface. 13 
At present it is not possible to predict which patients 
will develop restenosis following percutaneous trans- 
luminal angioplasty (PTA). If particular test results 
were found to correlate with restenosis, then such tests 
might be used to evaluate the risk of restenosis in 
individuals considering angioplasty. Determining the 
aetiological factors responsible for restenosis could 
also indicate which pharmacological gents hould be 
evaluated in future clinical trials aimed at reducing 
restenosis rates. The aim of the present study was to 
determine whether pre-angioplasty levels of PAI-1, 
vWF, fibrinogen, fibrin D-dimer, blood viscosity, 
plasma viscosity and haematocrit were predictive of 
subsequent restenosis following PTA. 
Patients and Methods 
Baseline 
A total of 102 men and women who underwent per- 
cutaneous transluminal balloon angioplasty for in- 
termittent claudication or rest pain at either the Royal 
Infirmary of Edinburgh or Glasgow Royal Infirmary 
between October 1991 and December 1992 were 
studied. Patients were not eligible for the study if they 
had undergone previous amputation or reconstructive 
surgery (to meet he requirements ofa parallel study~4), 
if they had ulceration or gangrene (which raise acute- 
phase reactant protein levels), if the dilated lesion 
was stented, or if the angioplasty was technically 
unsuccessful (defined as luminal narrowing of greater 
than 50% of the vessel diameter after dilation). Char- 
acteristics of the lesion to be dilated were noted from 
the pre-angioplasty angiogram, including whether it 
was an occlusion or a stenosis, the percentage stenosis 
of the arterial umen, its site (right or left leg, aortoiliac 
or femoropopliteal) and its length. If more than one 
lesion was dilated, only the most severe lesion ac- 
cording to the percentage stenosis of the arterial lumen 
was entered into the study. 
On the day prior to angioplasty, patients completed 
a medical questionnaire, including validated questions 
on smoking history and past medical history. Brachial 
blood pressure was measured supinely after 10 rain 
rest on a couch using a Hawksley random zero 
sphygmomanometer. Ankle systolic pressures were 
measured using a Doppler probe (Sonicaid, Chichester, 
U.K.) and the ankle brachial pressure index (ABPI) 
was calculated for each leg. On the same occasion, 
and before any adjuvant anticoagulant medication had 
been given, 25ml venous blood was taken without 
tourniquet while the patient was recumbent. 
In the laboratory, blood and plasma viscosities were 
measured from a blood sample that was anticoagulated 
with dry dipotassium EDTA (1.5mg/ml) at high shear 
rates (>300/s) in a Coulter-Harkness viscometer at 
37°C (coefficient of variation 1.2%). Haematocrit was 
measured with a Hawksley microcentrifuge (co- 
efficient of variation 0.6%), and fibrinogen in citrated 
plasma on a Coag-u-Mate analyser using a modified 
Clauss clotting method (coefficient of variation 6%). 
Fibrin D-dimer and von Willebrand factor antigens 
were assayed in frozen plasma from citrated blood 
using ELISA assays (AGEN, Parsippany and DAKO, 
Copenhagen, respectively) based on monoclonal anti- 
bodies (coefficients of variation 5%). Plasminogen ac- 
tivator inhibitor-1 activity was assayed on frozen 
plasma from citrated blood by means of an amidolytic 
assay (KABI, Stockholm). Total cholesterol was 
measured on the BM Hitachi 704 Analyser by the 
CHOP-PAP method and using reagents upplied by 
Boehringer-Mannheim. Quality control was monitored 
by means of blind duplicate samples that were taken 
intermittently throughout the study. 
Follow-up 
All patients till living were contacted by questionnaire 
2-3 years after their initial angioplasty to collect in- 
formation on use of aspirin, changes in smoking habit, 
and any further procedures for arterial disease of the 
lower limb, including angiography, repeat angioplasty 
and reconstructive surgery. Hospital in-patient notes 
of all patients were reviewed to ,confirm details of 
further procedures. All patients who had not under- 
gone a further procedure for proven restenosis at the 
original angioplasty site were invited to attend for 
duplex scanning. At each centre, colour duplex scan- 
ning was carried out between February 1995 and July 
1996 by a single, specially trained number of the 
research team using a diagram completed by the ra- 
diologist at the time of angioplasty to localise the 
original angioplasty site. In the case of technical dif- 
ficulty, the patient was rescanned by a consultant 
radiologisf. Both scanners were blind to the risk factor 
levels of each patient. Diameter changes at the relevant 
site were noted and Doppler velocity signals were 
measured. The degree of restenosis was assessed by 
the local increase of peak systolic velocity at the site 
of the stenosis compared with the peak systolic velocity 
of a nearby normal arterial segment (giving the peak 
systolic velocity index). A peak systolic velocity (PSV)- 
index of 2.0 or greater was taken to indicate a stenosis 
of 50% diameter eduction or more. ~5 
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Table 1. Baseline characteristics of patients and dilated lesions with and without restenosis at follow-up. 
No restenosis Restenosis 
Variables (n = 39) (n = 27) p-value 
Patient characteristics 
Age, mean years (95% CI) 
Males, % (n) 
Mean ABPI (95% CI)* 
Smoking 
current smoker, % (n) 53.8 (21) 
mean x/packyears (95% CI) 6.16 (5.24,7.10) 
Diabetes, % (n) 20.5 (8) 
Total cholesterol, mean mmol/1 (95% CI) 5.96 (5.61,6.30) 
Lesion characteristics** 
Site, aortoiliac vs. femoropopliteal, % (n) 52.5 (21) 
Leg, right vs. left % (n) 55.0 (22) 
Occlusion vs. stenosis, % (n) 17.5 (7) 
Stenosis, >50% vs. _< 50%, % (n) 86,7 (26) 
Length of lesion, <5cm vs. > cm, % (n) 75.7 (28) 
61.9 (58.6,65.2) 62.2 (58.5,65.9) NS 
70.0 (28) 70.4 (19) NS 
0.73 (0.66,0.80) 0.74 (0.65,0.84) NS 
33.3 (9) NS 
5.50 (4.23,6.77) NS 
1.1.1 (3) NS 
6.12 (5.63,6.68) NS 
37.0 (10) NS 
44.4 (12) NS 
40.7 (11) 0.04 
87.5 (14) NS 
65.4 (17) NS 
* Ankle brachial pressure index in leg with dilated lesion. 
** Percentage of first of the two options for each characteristic. 
NS not significant (p>0.1). 
Restenosis was defined as either (i) a further inter- 
vention or procedure for a restenosis at the original 
angioplasty site, confirmed clinically and/or  radio- 
logically, or (ii) an occlusion or a stenosis greater than 
50% at the site of the original angioplasty on duplex 
scanning. Patients were divided into a restenosis group 
or a no restenosis group according to these definitions. 
Patients were also split into four groups according to 
their duplex scan results: definite non-restenosis (PSV- 
index < 1.5), probable non-restenosis (1.5<PSV-index 
_< 2.0), probable restenosis (2.0 < PSV-index <2.5) and 
definite restenosis (PSV-index_> 2.5). 
Data are presented as means and 95% confidence 
intervals. Values for von Willebrand factor, fibrin D- 
dimer and plasminogen activator-1 activity were log 
transformed because of skewed distributions. The stat- 
istical package SPSS-X was used for the univariate 
analysis. Student's t-test for continuous variables and 
Chi-squared test for categorical variables were used 
to compare patients with and without restenosis. 
Multivariate analysis was performed using PROC 
GLM in SAS. The covariates used were age, sex, 
smoking habit at baseline (current smoker vs. never 
or ex-smoker), type of lesion (occlusion vs. stenosis), 
and smoking during the period between angioplasty 
and follow-up (yes vs. no). 
Results 
Of 102 patients entered into the study at baseline, 
eight died prior to follow-up and nine underwent a
further procedure due to restenosis at the original 
angioplasty site, including repeat angioplasty (n= 
3), stent insertion (n = 2), grafting (n =3) and lumbar 
sympathectomy (n = 1). Of the remaining 85 patients, 
25 moved away from the area or were unwill ing or 
unable to attend for re-examination a d three patients 
had a duplex scan that was unsuccessful for technical 
reasons. The overall restenosis rate in the 66 patients 
for whom the status of their original angioplasty site 
was known at follow-up (57 scanned and nine further 
procedures) was 41%, with a mean time to follow-up 
of 2.0 years in the restenosis group (n =27) and 2.8 
years in the no restenosis group (n =39). There was 
no significant difference in restenosis rate, age, sex or 
baseline smoking habit between patients examined 
in Glasgow compared to those in Edinburgh and 
subsequent analysis was carried out on the combined 
group. 
Baseline clinical characteristics of the patients in the 
restenosis group and the no restenosis group and 
the angiographic properties of the treated lesions are 
shown in Table 1. There was no significant difference 
in age, sex, ankle brachial pressure index, smoking 
habit, diabetes or total serum cholesterol between the 
two groups (p>0.1). Occluded lesions were more likely 
to restenose than those which were only partially 
stenosed prior to treatment (no restenosis group 
17.5% occlusions, restenosis group 40.7% occlusions, 
p _< 0.05). However, there was no sigificant difference 
in the site or length of the dilated lesion between the 
two groups (p>0.1). There was also no significant 
difference in the smoking habits or aspirin use of 
patients in the two groups during the period between 
angioplasty and follow up (p>0.1; Table 2). 
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Table 2. Smoking habits and aspirin use during period between angioplasty and 
follow-up in patients with and without restenosis at follow-up. 
No restenosis Restenosis 
Variables (n = 39) (n = 27) p-value 
Smoker vs. non-smoker, % (n) 
Mean ~packyears, 95% CI 
Aspirin use, % (n) 
48.7 (19) 44.4 (12) NS 
0.44 (0:25,0.63) 0.44 (0.22,0.66) NS 
67.5 (27) 80.0 (20) NS 
NS not significant (p>0.1). 
Table 3. Baseline haemostatic and rheological factor levels in patients with and without restenosis at follow- 
up, adjusted for age and sex. 
No restenosis (n=39) Restenosis (n=27) 
Variables Mean 95% CI Mean 95% CI p-value 
Whole blood viscosity (mPa.s) 
Plasma viscosity (mPa.s) 
Haematocrit (%) 
Fibrinogen (g/l) 
von Willebrand factor (IU/dl)* 
Fibrin D-dimer (ng/ml)* 
Plasminogen activator inhibitor (% pool)* 
3.37 (3.21, 3.53) 3.24 (3.15, 3.44) NS 
1.36 (1.33, 1.40) 1.33 (1.29, 1.37) NS 
44.2 (43.1, 45.3) 43.5 (42.2, 44.8) NS 
3.75 (3.50, 4.00) 3.31 (3.01, 3.61) 0.03 
130.3 (112.5, 151.0) 139.8 (117.6, 166.1) NS 
101.5 (83.9, 122.7) 90.0 (72.0, 112.6) NS 
112.2 (96.8, 129.9) 107.8 (91.4, 127.1) NS 
* Geometric mean (transformed 95% CI). 
NS not significant (p>0.1). 
Mean haemostatic and theological factor levels in 
the restenosis and no restenosis groups at baseline, 
adjusted for age and sex, are shown in Table 3. 
There was no significant difference in mean whole 
blood viscosity, plasma viscosity, haematocrit, von 
Willebrand factor, fibrin D-dimer or plasminogen ac- 
tivator inhibitor-1 activity between the two groups 
(p>0.1). Mean plasma fibrinogen was lower in the 
patients who restenosed than in the no restenosis 
group (no restenosis group 3.75g/1, 95% CI 3.50,4.00: 
restenosis group 3.31g/1, 95% CI 3.01,3.61: p<0.05). 
There was no difference in mean fibrinogen levels 
between subjects with a stenosis or occlusion at base- 
line (pre-angioplasty levels 3.59g/1 occlusions, 3.51g/1 
stenoses, p>0.1). Multivariate adjustment for smoking 
habit at baseline, type of lesion, or smoking habit 
during the period between angioplasty and follow- 
up made little difference, with fibrinogen remaining 
significantly higher in the no restenosis group in each 
instance (p < 0.05). 
Finally, patients were split into four groups ac- 
cording to their duplex scan results: definite non- 
restenosis (n=30), probable non-restenosis (n=9), 
probable restenosis (n = 9) and definite restenosis (n = 
18). There was no significant difference in mean hae- 
mostatic and rheological factors in patients in the 
definite restenosis group compared with those in the 
definite non-restenosis groups (p>0.1) except for 
plasma fibrinogen, which was slightly lower in the 
definite restenosis group (3.64 g/1 vs. 3.26 g/l ,  p = 0.08). 
Discussion 
Restenosis eriously limits the long-term efficacy of 
percutaneous transluminal angioplasty (PTA). In our 
study, the 2-3-year estenosis rate after PTA was 41%, 
which is comparable with the 25%-57% rates reported 
by others. 1Several studies have indicated patient char- 
acteristics that might influence restenosis rates, in- 
cluding increasing age 16 and presence of diabetes 
mell itusS "Is but such findings have been inconsistent. 
In our study, none of the patient demographic and 
clinical characteristics investigated were associated 
with restenosis. However most investigators have 
found that occlusions were more likely to restenose 
than were  s tenoses  ~6'19'2° ar id  this was also our ex- 
perience. However, contrary to most, but not all, pre- 
vious studies, 16'19'2° other characteristics of the dilated 
lesion such as site and length did not affect restenosis. 
Unfortunately we did not have a large enough sample 
size to meaningfully analyse occlusions and stenoses 
or lesions in the aortoiliac and femoropopliteal systems 
separately. 
Although plasminogen activator inhibitor-1 (PAI-1) 
activity and von Willebrand factor (vWF) levels are 
elevated in patients with peripheral arterial disease, 4'6 
concentrations of these factors measured immediately 
prior to angioplasty, were not associated with re- 
stenosis 2-3 years after PTA. The role of PAI-lactivity 
and vWF in restenosis following PTA of the iliac 
and femoropopliteal rteries has not previously been 
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investigated. However, our results are consistent with 
studies of coronary angioplasty, in which pre-angio- 
plasty PAI-1 activity was no different, 2~-z3 or even 
diminished 24in patients developing restenosis com- 
pared with those remaining patent. Similarly, no re- 
lationship was demonstrated between pre-angioplasty 
vWF and restenosis of the coronary arteries, although 
vWF levels measured immediately after coronary an- 
gioplasty did predict restenosis, a3 Because vWF is syn- 
thesized by endothelial cells, this latter result may 
have reflected a more severe ndothelial injury during 
angioplasty in patients who develop a more intense 
proliferative reaction during follow up. 
Elevated plasma fibrinogen is a risk factor for the 
development of peripheral arterial disease, 2~ is as- 
sociated with the extent of disease at angiography, 14'26 
and could potentially increase the risk of restenosis 
after angioplasty through its atherogenic and throm- 
bogenic properties. However, we found lower fib- 
rinogen levels prior to PTA in patients who restenosed 
than in those remaining patent. Pre-angioplasty 
plasma fibrinogen has not previously been studied 
as a predictor of restenosis in patients undergoing 
"routine" PTA for intermittent claudication or rest 
pain. Fibrinogen levels greater than 4.9g/1 were as- 
sociated with an increased rate of surgical re- 
vascularisation r amputation i subjects with critical 
lower limb ischaemia undergoing PTA as part of a 
clinical trial, but in some subjects fibrinogen was meas- 
ured immediately after PTAY Fibrinogen measured 
immediately prior to coronary angioplasty did not 
predict restenosis in two substantial studies, 23'24 al- 
though pre-angioplasty levels were higher in six 
patients who restenosed compared with 17 remaining 
patent, 28 and fibrinogen measured within 6 months 
after coronary angioplasty did predict subsequent re- 
stenosis. R3Our result of a lower fibrinogen level in 
those who restenosed, which persisted after controlling 
for age, sex, smoking habit before and after angioplasty 
and the type of lesion dilated is difficult to explain. It 
may have been a chance finding or due to a selection 
effect, since fibrinogen is a strong predictor of early 
death in patients with peripheral arterial disease. 29'3° 
Alternatively, it is possible that elevated fibrinogen 
levels might affect the characteristics of a lesion (for 
example its composition or compliance) in such a 
way as to make it less likely to restenose following 
angioplasty. Further investigation will be required to 
confirm or refute this finding. 
Elevated fibrin D-dimer is associated with increasing 
severity of peripheral arterial disease 5'26 and with the 
incidence of cardiovascular events. 31 However, we did 
not find any difference infibrin D-dimer levels between 
subjects who restenosed and those remaining patent. 
In a recent study, eight subjects who failed to dem- 
onstrate a standard increase in ankle brachial pressure 
index within 30 days of a technically successful femoro- 
popliteal angioplasty had higher fibrin D-dimer than 
23 subjects defined as patent. 32 However the results of 
this relatively small study, with patency measured in 
days, may have been affected by a higher percentage 
of subjects with gangrene (associated with elevated 
fibrin D-dimer levels) in the restenosis group. In our 
study, subjects with gangrene were excluded. 
Blood viscosity, the intrinsic resistance to flow in 
vessels, and two of its major determinants, plasma 
viscosity and haematocrit, are also higher in subjects 
with peripheral arterial disease, 3'6 and predict cardio- 
vascular events in the general population. 33These 
rheological factors may enhance both atherogenesis 
and thrombosis by prolonging contact between con- 
stituents of the blood and the endothelial surface. 13 
However, in our study, which is the first to investigate 
the relationship between rheological factors and ar- 
terial restenosis, there was no association between 
blood viscosity, plasma viscosity or haematocrit and 
subsequent restenosis, uggesting that rheology is not 
involved in the aetiology of restenosis after PTA. 
There are several methodological f ctors which may 
have affected the results of this study. Firstly, we chose 
duplex scanning to monitor estenosis, as this is a non- 
invasive test with the advantage oflocalising abnormal 
arterial segments and categorising disease severity at 
specific angioplasty sites (unlike tests such as the ankle 
brachial pressure index and walking distance). With 
angiography as the gold-standard, peak systolic velo- 
city ratios >2 on duplex are 95% specific and at least 
85% sensitive at detecting stenoses affecting more than 
50% of the arterial umen. 34 However, since duplex 
scanning was not performed immediately after an- 
gioplasty, the degree of residual stenosis after the 
procedure was not considered in the definition of 
restenosis (although all lesions improved to at least 
50% residual stenosis following dilatation). Although 
this may be relevant when considering aetiological 
aspects of restenosis, clinically it is the degree of 
stenosis at any one point in time that is most likely to 
be important. Secondly, due to the study design, we 
were not able to analyse the results according to 
• time to restenosis. Ideally, subjects would have been 
followed-up by duplex scanning within a few days 
of angioplasty and at regular 3-6-monthly intervals 
thereafter. Although this approach may have been 
more likely to identify factors involved preferentially 
in early restenosis, we were still able to identify sub- 
jects with lesions that restenosed at any time within 
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2-3 years of angioplasty, and who might therefore 
have been expected to demonstrate different hae- 
mostatic and rheological factor levels according to our 
initial hypothesis. Finally, the number of subjects in 
the study may not have been sufficient o detect rue 
differences in haemostatic and rheological factor levels 
if these were only small. 
In conclusion, we failed to demonstrate a re- 
lationship between raised pre-angioplasty levels of 
haemostatic and rheological factors and restenosis f01- 
lowing percutaneous transluminal angioplasty of the 
arteries of the lower limbs. These results are consistent 
with previous tudies on coronary angioplasty, but in 
contrast to findings that fibrinogen, fibrin D-dimer 
and von Willebrand factor levels are predictive of 
occlusion of peripheral arterial grafts, 35'36 which sug- 
gests that the mechanisms of graft occlusion and of 
restenosis post-angioplasty may be different. Thus, 
circulating levels of haemostatic and rheological fac- 
tors found prior to angioplasty may not be important 
in the development of restenosis and are unlikely to 
be helpful in the prediction of patients who will require 
further intervention. However, occlusion lesions were 
more likely to restenose than stenoses, and this is 
consistent with previous tudies which indicated that 
it is the properties of the dilated lesion rather than of 
the patient which are important in predicting re- 
stenosis. 
Acknowledgements 
We thank the British Heart Foundation for financial support, Dr Paul 
Allan, Dr Mike Sproule and Mrs Eileen Kerracher for performing the 
duplex scanning and Dr Amanda Lee and Mr Phillip Mowbray for 
statistical assistance. 
References 
1 PRICE JF, FOWKES FGR. Effectiveness of percutaneous tran- 
sluminal angioplasty for lower limb atherosclerosis. In: Green- 
halgh; Fowkes (eds). Trials and Tribulations of Vascular Surgery. 
London: W.B. Saunders Co. 1996: 245-257. 
2 HERMANS WRIt, RENSING BJ, STRAUSS BH, SERRUYS PW. Pre- 
vention of restenosis after percutaneous transluminal coronary 
angioplasty: The search for a "magic bullet". Am Heart J 1991; 
122: 171-187. 
3 LowE GDO, FOWKES FGR, DAWES J, DONNAN PT, LENNIE SE, 
HOUSLEY E. Blood viscosity, fibrinogen and activation of co- 
agulation and leukocytes in peripheral arterial disease and the 
normal population in the Edinburgh Artery Study. Circulation 
1993; 87: 1915-1920. 
4 SMITH FB, LOWE GDO, FOWKES FGR, RUMLEY A, RUMLEY AG, 
DONNAN PT, HOUSLEY E. Smoking, haemostatic factors and lipid 
peroxides in a population case control study of peripheral arterial 
disease. Atherosclerosis 1993; 102: 155-162. 
5 LEE AJ, FOWKES FGR, LOWE GDO, RUMLEY A. Fibrin D-dimer, 
haemostatic factors and peripheral arterial disease. Thromb Haem- 
ost 1995; 74: 828-832. 
6 LEE AJ, FOWKES FGR, RATTRAY A, RUMLEY A, LOWE GDO. 
Haemostatic and rheological factors in intermittent claudication: 
the influence of smoking and extent of arterial disease. Br l 
Haematol 1996; 92: 226-230. 
7 GLAGOV S. Intimal hyperplasia, vascular modelling, and re- 
stenosis problem. Circulation 1994; 89: 2888-2891. 
8 HAUDENSCHILD CC. Pathobiology of restenosis after angioplasty. 
Am f Med 1993; 94 (Suppl. 4A): 40S-44S. 
9 COLLEN D. Report of the meeting of the Subcommittee on 
Fibrinolysis, San Diego, July 13, 1985. Thromb Haemost 1985; 54: 
893. 
10 DE GROOT PG, SIXMA JJ. Role of yon Willebrand factor in the 
vessel walt. Semin Thrornb Hemost 1987; 13: 416-424. 
11 DANG CV, BELL WR. The normal and morbid biology of fib- 
rinogen. Am J Med 1989; 87: 567. 
12 LIP GHY, LowE GDO. Fibrin D-dimer; a useful clinical marker 
of thrombogenesis. Clin Sci 1995; 89: 205-214. 
13 LowE GDO. Blood v~scosity and cardiovascular disease. Thromb 
Haemost 1992; 67: 494-498. 
14 SMITH FB, LEE AJ, FOWKES FGR, LOWE GDO, RUMLE¥ A. Smoking, 
haemostatic factors and severity of aorto-iliac and femoro-pop- 
liteal disease. Thromb Haemost 1996; 75: 19-24. 
15 JAGER KA, PHILLIPS DJ, MARTIN RL et al. Non-invasive mapping 
of lower limb arterial lesions. Ultrasound Med Biol 1985; 11: 
515-521. 
16 JEANS WD, ARMSTRONG S, COLE SEA, HORROCKS M, BAIRD RN. 
Fate of patients undergoing transluminal ngioplasty for lower 
limb ischaemia. Radiology 1990; 177: 559-564. 
17 SPENCE RK, FREIMAN DB, GATENBY R et al. Long-term results of 
transluminal angioplasty of the iliac and femoral arteries. Arch 
Surg 1981; 116: 1377-1386. 
18 CAPEK P, McLEAN GK, BERKOWITZ HD. Femoropopliteal n- 
gioplasty. Factors influencing long-term success. Circulation 1991; 
83 (Suppl. I): I70-I80. 
18 BECQUEMIN JP, CAVlLLON A, HAIDUC ]7. Surgical transluminal 
femoropopliteal ngioplasty: multivariate analysis outcome. ]
Vasc Surg 1994; 19: 495-502. 
20 JOHNSTON KW, RAE M, HOGG-JoHNSTON SA et al. Five year 
results of a prospective study of percutaneous transluminal 
angioplasty. Ann Surg 1987; 206: 403-413. 
21 HUBER K, JORG M, PROBST P, SCHUSTER E, GANG I, KAINDL F, 
BINDER BR. A decrease in plasminogen activator inhibitor-1 
activity after successful percutaneous transluminal coronary an- 
giop!asty is associated with a significantly reduced risk for 
coronary restenosis. Thromb Haemost 1992; 67: 209-213. 
22 BRACK MJ, MORE R~ PRINGLE S, GERSHLICK AH. Absence of a 
prothrombotic state in restenotic patients? Coronary Artery Disease 
1994; 5: 501-506. 
23 MONTALESCOT G, ANKRI A, VICAUT E, DROBINSKI G, GROSGOGEAT 
Y, THOMAS D. Fibrinogen after coronary angioplasty as a risk 
factor for restenosis. Circulation 1995; 92: 31-38. 
24 SHAH PK' AMIN J. L°w high density lip°pr°tein level is ass°ciated 
with increased restenosis rate after coronary angioplasty. Cir- 
culation 1992; 85: 1279-1285. 
25 KANNEL WB, D'AGOSTINO RB. Update of fibrinogen as a major 
cardiovascular risk factor; the Framingham Study. J Am Coll 
Cardiol 1990; 15: 156A (abstract). 
26 WOODBURN KR, LOWE GDO, RUMLEY A, LOVE J, POLLOCK JG. 
Relation of haemostatic, fibrinolytic, and rheological variables 
to the angiographic extent of peripheral arterial occlusive dis- 
eases. Int Angiol 1995; 14: 346-352. 
27 MATSI PJ, MANNINEN HI, LAAKSO M, JAAKKOLA P. Impact of risk 
factors on limb salvage after angioplasty in chronic critical ower 
limb ischaemia. Angiology 1994; 45: 797-804. 
28 BENCHIMOL D, BONNET J, BENCHIMOL H, DROUILLET F, DUPLAA 
C, COUFFINHAL T, DESGRANGES C/ BRICAUD H. Biological risk 
factors for restenosis after percutaneous transluminal an- 
gioplasty. Int J Cardiol 1993; 38: 7-18. 
29 BANERJEE AK, PEARSON J, GILLILAND EL, et aI. A six year 
Eur J Vasc Endovasc Surg Vol 14, November 1997 
398 J.F. Price et aL 
prospective study of fibrinogen and other risk factors associated 
with mortality in stable claudicants. Thromb Haernost 1992; 68: 
261-263. 
30 FOWKES FGR, LOWE GDO, HousI~EY E et al. Cross linked fibrin 
degradation products, progression of peripheral arterial disease 
and risk of coronary heart disease. Lancet 1993; 342: 84-86. 
31 LowE GDO, RUMLEY A, YARNELL JWG, SWEETNAM PM, THOMAS 
HF. Fibrin D-dimer, von Willebrand factor and tissue plas- 
minogen activator antigens are predictors of major ischaemic 
heart disease: the Caerphilly Study. Blood Coag Fibrinolysis 1995; 
6: 156-157. 
32 JORGENSEN B, NIELSEN JD, NOI~GXRD J, HELLIGS@ P, B~EKGAARD 
R, EGEBLAD M. Cross-linked fibrin degredation products (XL- 
FDP) as marker of early rethrombosis in percutaneous trans- 
luminal angioplasty. Eur J Vasc Surg 1993; 7: 720-724. 
33 LOWE GDO, LEE AJ, RUMLEY A, P~ICE JF, FOWKES FGR. Blood 
viscosity and risk of cardiovascular events: the Edinburgh Artery' 
Study. Br J Haematol 1997; 96: 168-173. 
34 LENG GC. Colour duplex ultrasound. In: The Measurement of
Peripheral Vascular Disease in Epidemiological Surveys. M.D. 
Thesis University of Edinburgh 139-175, 1993. 
35 WISEMAN S, KENCHINGTON G, DAIN R et aL Influence of smoking 
and plasma factors on patency of femoropopliteal vein grafts. 
BMJ 1989; 299: 643-646. 
36 WOODBURN KR, RUMLEY A, LOVE J, MURRAY GD, LOWE GDO. 
Clinical, biochemical and rheological factors affecting the out- 
come of infra-inguinal bypass grafting. J Vasc Surg 1996; 24: 
639-646. 
Accepted 9 May 1997 
Eur J Vasc Endovasc Surg Vol 14, November 1997 
